OTCM
BMKDF
Market cap39mUSD
Oct 06, Last price
0.38USD
1D
-5.11%
1Q
-1.41%
Jan 2017
300.96%
IPO
9.25%
Name
BioMark Diagnostics Inc
Chart & performance
P/E
—
P/S
942.32
EPS
—
Div yield, %
—
Shrs. gr., 5y
7.47%
Rev. gr., 5y
-10.15%
Revenues
60k
-61.23%
Net income
-1m
L-23.35%
CFO
-1m
L-0.40%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BioMark Diagnostics Inc. is an oncology-focused firm that develops sophisticated diagnostic tools for cancer. These solutions are designed to aid in the identification of the disease, its ongoing monitoring, and the assessment of initial therapeutic interventions. The company has a research partnership with the Icahn School of Medicine, under which they conduct clinical studies concentrating on the early detection of lung cancer. Established in 2014, BioMark Diagnostics Inc. has its main office in Richmond, Canada, and functions as a subsidiary of Biomark Technologies Inc.
Key people
Guoyu Huang
Chief Financial Officer
James Lavender
Director · since 2025
Kai-ming Cheng
Independent Director · since 2014
Bramhanand Ramjiawan
Independent Director · since 2014
Headquarters & legal address
165 – 10551 Shellbridge Way
Richmond, BC V6X 2W8
CA
Richmond, BC V6X 2W8
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||